Global Live Attenuated Influenza Vaccine (LAIV) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Live Attenuated Influenza Vaccine (LAIV) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Live Attenuated Influenza Vaccine (LAIV) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Live Attenuated Influenza Vaccine (LAIV) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Live Attenuated Influenza Vaccine (LAIV) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Live Attenuated Influenza Vaccine (LAIV) key manufacturers include Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc. Sanofi Pasteur, AstraZeneca, CSL are top 3 players and held % sales share in total in 2022.
Live Attenuated Influenza Vaccine (LAIV) can be divided into Trivalent Flu Vaccine and Quadrivalent Flu Vaccine, etc. Trivalent Flu Vaccine is the mainstream product in the market, accounting for % sales share globally in 2022.
Live Attenuated Influenza Vaccine (LAIV) is widely used in various fields, such as Hospital, Clinic, Public Health Agency and Other, etc. Hospital provides greatest supports to the Live Attenuated Influenza Vaccine (LAIV) industry development. In 2022, global % sales of Live Attenuated Influenza Vaccine (LAIV) went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Live Attenuated Influenza Vaccine (LAIV) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Segment by Type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Hospital
Clinic
Public Health Agency
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Live Attenuated Influenza Vaccine (LAIV) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Live Attenuated Influenza Vaccine (LAIV), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Live Attenuated Influenza Vaccine (LAIV) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Live Attenuated Influenza Vaccine (LAIV) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Live Attenuated Influenza Vaccine (LAIV) introduction, etc. Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Live Attenuated Influenza Vaccine (LAIV) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for Live Attenuated Influenza Vaccine (LAIV) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Live Attenuated Influenza Vaccine (LAIV) key manufacturers include Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc. Sanofi Pasteur, AstraZeneca, CSL are top 3 players and held % sales share in total in 2022.
Live Attenuated Influenza Vaccine (LAIV) can be divided into Trivalent Flu Vaccine and Quadrivalent Flu Vaccine, etc. Trivalent Flu Vaccine is the mainstream product in the market, accounting for % sales share globally in 2022.
Live Attenuated Influenza Vaccine (LAIV) is widely used in various fields, such as Hospital, Clinic, Public Health Agency and Other, etc. Hospital provides greatest supports to the Live Attenuated Influenza Vaccine (LAIV) industry development. In 2022, global % sales of Live Attenuated Influenza Vaccine (LAIV) went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Live Attenuated Influenza Vaccine (LAIV) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Segment by Type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Segment by Application
Hospital
Clinic
Public Health Agency
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Live Attenuated Influenza Vaccine (LAIV) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Live Attenuated Influenza Vaccine (LAIV), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Live Attenuated Influenza Vaccine (LAIV) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Live Attenuated Influenza Vaccine (LAIV) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Live Attenuated Influenza Vaccine (LAIV) introduction, etc. Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Live Attenuated Influenza Vaccine (LAIV) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices